2026 Erkki Ruoslahti: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Best Scientists	194	364	341	241	222	704	153152
Biology and Biochemistry	196	37	35	30	28	653	157348

Research.com Recognitions

2026 - Research.com Biology and Biochemistry in United States Leader Award
2025 - Research.com Best Scientists Award
2025 - Research.com Biology and Biochemistry in United States Leader Award
2023 - Research.com Biology and Biochemistry in United States Leader Award
2014 - Fellow, National Academy of Inventors
2005 - Japan Prize for fundamental contribution in elucidating the Molecular Mechanisms of Cell Adhesion.
2002 - Member of the National Academy of Medicine (NAM)
1999 - Member of the National Academy of Sciences
1997 - Canada Gairdner International Award
1993 - Fellow of the American Academy of Arts and Sciences
1990 - Robert J. and Claire Pasarow Foundation Medical Research Award

Overview

Erkki Ruoslahti is affiliated with the Sanford Burnham Prebys Medical Discovery Institute in the United States. Their research spans several key areas in the biomedical sciences, with a strong emphasis on medicine and biochemistry, genetics, and molecular biology. Within these broader fields, they have contributed notably to molecular biology, oncology, immunology, immunology and allergy, and pulmonary and respiratory medicine.

Their work encompasses various topics such as cell adhesion molecules research, RNA interference and gene delivery, wound healing and treatments, antimicrobial peptides and activities, advanced biosensing and bioanalysis techniques, prostate cancer treatment and research, and monoclonal and polyclonal antibodies research.

Erkki Ruoslahti has several recent publications that illustrate these research interests:

Tumor-penetrating therapy for β5 integrin-rich pancreas cancer, 2021, Nature Communications
iRGD-Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis, 2021, Advanced Functional Materials
Silver Nanocarriers Targeted with a CendR Peptide Potentiate the Cytotoxic Activity of an Anticancer Drug, 2020, Advanced Therapeutics
Systemically administered wound-homing peptide accelerates wound healing by modulating syndecan-4 function, 2023, Nature Communications
Molecular ZIP codes in targeted drug delivery, 2022, Proceedings of the National Academy of Sciences

The scientist frequently collaborates with a number of coauthors, including Kazuki N. Sugahara, Tatiana Hurtado de Mendoza, Tambet Teesalu, Evangeline Mose, and Gregory P. Botta.

Erkki Ruoslahti's publications are commonly found in notable scientific venues such as bioRxiv (Cold Spring Harbor Laboratory), Nature Communications, Advanced Functional Materials, Proceedings of the National Academy of Sciences, and JAMA.

Throughout their career, they have been recognized with various awards including:

Fellow, National Academy of Inventors (2014)
Japan Prize (2005) for fundamental contributions in elucidating the molecular mechanisms of cell adhesion
Member of the National Academy of Medicine (NAM) (2002)
Member of the National Academy of Sciences (1999)
Canada Gairdner International Award (1997)
Fellow of the American Academy of Arts and Sciences (1993)
Robert J. and Claire Pasarow Foundation Medical Research Award (1990)

Best Publications

New perspectives in cell adhesion : RGD and integrins

Erkki Ruoslahti;Michael D. Pierschbacher

7624
Citations
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule

Michael D. Pierschbacher;Erkki Ruoslahti

5726
Citations
RGD and other recognition sequences for integrins.

Erkki Ruoslahti

4852
Citations
Binding of soluble form of fibroblast surface protein, fibronectin, to collagen.

Eva Engvall;Erkki Ruoslahti

2903
Citations
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model

Wadih Arap;Renata Pasqualini;Erkki Ruoslahti

2812
Citations
Negative regulation of transforming growth factor-β by the proteoglycan decorin

Yu Yamaguchi;David M. Mann;Erkki Ruoslahti

2255
Citations
Biodegradable luminescent porous silicon nanoparticles for in vivo applications.

Ji-Ho Park;Luo Gu;Geoffrey von Maltzahn;Erkki Ruoslahti

2170
Citations
Nanocrystal targeting in vivo

Maria E. Åkerman;Warren C. W. Chan;Pirjo Laakkonen;Sangeeta N. Bhatia

2100
Citations
Arg-Gly-Asp: a versatile cell recognition signal.

Erkki Ruoslahti;Michael D. Pierschbacher

2094
Citations
Fibronectin and its receptors.

Erkki Ruoslahti

2043
Citations
Proteoglycans as modulators of growth factor activities

Erkki Ruoslahti;Yu Yamaguchi

2008
Citations
Integrins and anoikis

Steven M Frisch;Erkki Ruoslahti

1737
Citations
Control of adhesion-dependent cell survival by focal adhesion kinase.

S M Frisch;K Vuori;E Ruoslahti;P Y Chan-Hui

1659
Citations
Organ targeting In vivo using phage display peptide libraries

Renata Pasqualini;Erkki Ruoslahti

1656
Citations
Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor

Robert Pytela;Michael D. Pierschbacher;Erkki Ruoslahti

1606
Citations
Transforming growth factor-beta in disease: the dark side of tissue repair.

Wayne A. Border;Erkki Ruoslahti

1540
Citations
Anchorage dependence, integrins, and apoptosis

Erkki Ruoslahti;John C. Reed

1527
Citations
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1

Wayne A. Border;Seiya Okuda;Lucia R. Languino;Michael B. Sporn

1514
Citations
Natural inhibitor of transforming growth factor-|[beta]| protects against scarring in experimental kidney disease

Wayne A. Border;Nancy A. Noble;Tatsuo Yamamoto;John R. Harper

1461
Citations
Tissue-penetrating delivery of compounds and nanoparticles into tumors

Kazuki N. Sugahara;Tambet Teesalu;Priya Prakash Karmali;Venkata Ramana Kotamraju

1195
Citations